Literature DB >> 26920677

Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.

Aoibhinn McDonnell1, Betsy Schulman2, Zahid Ali1, Sulayman D Dib-Hajj2, Fiona Brock3, Sonia Cobain3, Tina Mainka4, Jan Vollert5, Sanela Tarabar6, Stephen G Waxman2.   

Abstract

Inherited erythromelalgia, the first human pain syndrome linked to voltage-gated sodium channels, is widely regarded as a genetic model of human pain. Because inherited erythromelalgia was linked to gain-of-function changes of sodium channel Na(v)1.7 only a decade ago, the literature has mainly consisted of reports of genetic and/or clinical characterization of individual patients. This paper describes the pattern of pain, natural history, somatosensory profile, psychosocial status and olfactory testing of 13 subjects with primary inherited erythromelalgia with mutations of SCN9A, the gene encoding Na(v)1.7. Subjects were clinically profiled using questionnaires, quantitative sensory testing and olfaction testing during the in-clinic phase of the study. In addition, a detailed pain phenotype for each subject was obtained over a 3-month period at home using diaries, enabling subjects to self-report pain attacks, potential triggers, duration and severity of pain. All subjects reported pain and heat in the extremities (usually feet and/or hands), with pain attacks triggered by heat or exercise and relieved mainly by non-pharmacological manoeuvres such as cooling. A large proportion of pain attacks (355/1099; 32%) did not involve a specific trigger. There was considerable variability in the number, duration and severity of pain attacks between subjects, even those carrying the same mutation within a family, and within individuals over the 12-13 week observation period. Most subjects (11/13) had pain between attacks. For these subjects, mean pain severity between pain attacks was usually lower than that during an attack. Olfaction testing using the Sniffin'T test did not demonstrate hyperosmia. One subject had evidence of orthostatic hypotension. Overall, there was a statistically significant correlation between total Hospital Anxiety and Depression Scale scores (P= 0.005) and pain between attacks and for Hospital Anxiety and Depression Scale Depression scores and pain between attacks (P= 0.001). Hospital Anxiety and Depression Scale scores for five subjects were below the threshold for mild anxiety or depression and none of the 13 subjects were severely anxious and/or depressed. Quantitative sensory testing revealed significantly increased detection thresholds for cold and warm stimuli at affected, compared to unaffected sites. By contrast, significantly decreased cold and heat pain thresholds were found at unaffected sites. Sensory profiles varied considerably between affected and unaffected sites, suggesting the existence of small fibre neuropathy in symptomatic sites. This in-depth clinical characterization of a well-defined inherited erythromelalgia population indicates the importance of characterizing the pain phenotype in individuals before undertaking clinical trials, given the inherent variability of pain both between and within inherited erythromelalgia subjects, even those within a family who carry the same mutation.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Nav1.7; clinical phenotyping; inherited erythromelalgia; quantitative sensory testing; small fibre neuropathy

Mesh:

Substances:

Year:  2016        PMID: 26920677     DOI: 10.1093/brain/aww007

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  17 in total

Review 1.  Emerging Targets for the Management of Osteoarthritis Pain.

Authors:  Anne-Marie Malfait; Richard J Miller
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

2.  [Erythromelalgia: skin redness and pain].

Authors:  M Dusch; M Schmelz
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

Review 3.  Sodium channels in pain disorders: pathophysiology and prospects for treatment.

Authors:  Sulayman D Dib-Hajj; Paul Geha; Stephen G Waxman
Journal:  Pain       Date:  2017-04       Impact factor: 6.961

Review 4.  Status of peripheral sodium channel blockers for non-addictive pain treatment.

Authors:  Matthew Alsaloum; Grant P Higerd; Philip R Effraim; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2020-10-27       Impact factor: 42.937

Review 5.  Psychedelics in the Treatment of Headache and Chronic Pain Disorders.

Authors:  Emmanuelle A D Schindler
Journal:  Curr Top Behav Neurosci       Date:  2022

6.  Resilience to Pain: A Peripheral Component Identified Using Induced Pluripotent Stem Cells and Dynamic Clamp.

Authors:  Malgorzata A Mis; Yang Yang; Brian S Tanaka; Carolina Gomis-Perez; Shujun Liu; Fadia Dib-Hajj; Talia Adi; Rolando Garcia-Milian; Betsy R Schulman; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  J Neurosci       Date:  2018-11-20       Impact factor: 6.167

Review 7.  Resilience to Stress and Resilience to Pain: Lessons from Molecular Neurobiology and Genetics.

Authors:  Eric J Nestler; Stephen G Waxman
Journal:  Trends Mol Med       Date:  2020-04-18       Impact factor: 11.951

8.  µ-TRTX-Ca1a: a novel neurotoxin from Cyriopagopus albostriatus with analgesic effects.

Authors:  Yun-Xiao Zhang; De-Zheng Peng; Qing-Feng Zhang; Biao Huang; Qiu-Chu Yang; Dong-Fang Tang; Min-Zhi Chen; Ming-Qiang Rong; Zhong-Hua Liu
Journal:  Acta Pharmacol Sin       Date:  2018-10-31       Impact factor: 6.150

Review 9.  Using stratified medicine to understand, diagnose, and treat neuropathic pain.

Authors:  Andreas C Themistocleous; Geert Crombez; Georgios Baskozos; David L Bennett
Journal:  Pain       Date:  2018-09       Impact factor: 7.926

10.  SCN10A Mutation in a Patient with Erythromelalgia Enhances C-Fiber Activity Dependent Slowing.

Authors:  Andreas M Kist; Dagrun Sagafos; Anthony M Rush; Cristian Neacsu; Esther Eberhardt; Roland Schmidt; Lars Kristian Lunden; Kristin Ørstavik; Luisa Kaluza; Jannis Meents; Zhiping Zhang; Thomas Hedley Carr; Hugh Salter; David Malinowsky; Patrik Wollberg; Johannes Krupp; Inge Petter Kleggetveit; Martin Schmelz; Ellen Jørum; Angelika Lampert; Barbara Namer
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.